Bristol-Myers (NYSE:BMY)Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK), are among the most widely owned dividend paying drug companies and sales at all three are feeling the patent pinch.

With the patent cliff ready to erase $66 billion in industry sales next year and shares trading at lofty levels, should these three be in your dividend portfolio?

In the following slideshow, you'll find info on which patent losses are taking their toll, which products are driving sales higher, and whether dividend payouts could grow or shrink.

Todd Campbell has no position in any stocks mentioned. He owns E.B. Capital Markets, LLC, whose clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC, whose clients do not have positions in the companies mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.